A Novel Atypical Retinoid Endowed with Proapoptotic and Antitumor Activity-Reference-Cited by-同舟云学术

A Novel Atypical Retinoid Endowed with Proapoptotic and Antitumor Activity

Published:2003-02-19 Issue:6 Volume:46 Page:909-912
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cincinelli Raffaella¹,Dallavalle Sabrina¹,Merlini Lucio¹,Penco Sergio¹,Pisano Claudio¹,Carminati Paolo¹,Giannini Giuseppe¹,Vesci Loredana¹,Gaetano Carlo¹,Illy Barbara¹,Zuco Valentina¹,Supino Rosanna¹,Zunino Franco¹

Affiliation:

1. Dipartimento di Scienze Molecolari Agroalimentari, Università di Milano, Milano, Italy, R & D, Sigma-tau, Pomezia, Italy, Unità Operativa Farmacologia Preclinica, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy, Laboratorio Patologia Vascolare, Istituto Dermopatico dell'Immacolata, Rome, Italy, and Laboratorio Terapia Genica e Biologia Vascolare, Istituto Cardiologico “Fondazione I. Monzino”, Milano, Italy

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm025593y

Reference9 articles.

1. The promise of retinoids to fight against cancer

2. Classical and novel retinoids: their targets in cancer therapy

3. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel ST1926 Nanoparticle Drug Formulation Enhances Drug Therapeutic Efficiency in Colorectal Cancer Xenografted Mice;Nanomaterials;2024-08-23

2. Reduced Levels of Lagging Strand Polymerases Shape Stem Cell Chromatin;2024-04-29

3. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial;Nature Communications;2024-03-30

4. Targeting breast cancer stem cells through retinoids: A new hope for treatment;Critical Reviews in Oncology/Hematology;2023-12

5. Development and Challenges of Synthetic Retinoid Formulations in Cancer;Current Drug Delivery;2023-11